Clinico-pathological analysis of myelodysplastic syndromes according to French-American-British classification and international prognostic scoring system

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 5, 2004, Pages 589-595

  Lau, Lee Gong ^a,b   Chng, W J ^a,b   Liu, T C ^a,b   Tan, L K ^a,b   Ong, K H ^a,b   Mow, B M F ^b   Kueh, Y K ^b  

^a National University Hospital ^*

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Asian; Cytogenetics; Retrospective study

Indexed keywords

HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; BIOPSY; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLASSIFICATION; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOGENETICS; FEMALE; HUMAN; KARYOTYPE; MALE; MYELODYSPLASTIC SYNDROME; PROGNOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SCORING SYSTEM; SURVIVAL;

EID: 10344266439     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Hellstrom-Lindberg E, Willman C, Barrett AJ, Saunthararajah Y. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2000:110-32.
2. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340: 1649-60.
3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
4. Varela BL, Chuang C, Woll JE, Bennett JM. Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system. Hematol Oncol 1985;3:55-63.
5. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425-33.
6. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395-408.
7. Goasguen JE, Garand R, Bizet M, Bremond JL, Gardais J, Callat MP, et al. Prognostic factors of myelodysplastic syndromes: a simplified 3-D scoring system. Leukemia Res 1990;14:255-62.
8. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-9.
9. Jacobs RH, Cornbleet MA, Vardiman JW, Larson RA, Le Beau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986;67:1765-72.
10. Suciu S, Kuse R, Weh HJ, Hossfeld DK. Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 1990;44:15-26.
11. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 1993;7:499-508.
12. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated into a new scoring system: a report on 408 cases. Leukemia 1993;7:1315-23.
13. Parlier V, van Melle G, Beris P, Schmidt PM, Tobler A, Haller E, et al. Prediction of 18-month survival in patients with primary myelodysplastic syndrome. A regression model and a scoring system based on the combination of chromosome findings and the Bournemouth score. Cancer Genet Cytogenet 1995;81:158-65.
14. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
15. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
16. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983-92.
17. Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001;98: 2935-41.
18. Mitelman F, editor. ISCN: An International System for Human Cytogenetic Nomenclature. Basel: Karger, 1995.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Oguma S, Yoshida Y, Uchino H, Maekawa T, Nomura T, Mizoguchi H. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 patients. Leuk Res 1995;19:219-25.
21. Tien HF, Wang CH, Chuang SM, Chow JM, Lee FY, Liu MC, et al. Cytogenetic studies, ras mutation and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan. Cancer Genet Cytogenet 1994;74:40-9.
22. Intragumtornchai T, Prayoonwiwat W, Swasdikul D, Suwanwela N, Chaimongkol B, Jootar S, et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res 1998;22:453-60.
23. Estey E, Rearing M, Pierce S, Beran M. Application of the International Scoring System for myelodysplasia to M.D. Anderson patients. Blood 1997;90:2843-6.
24. Belli C, Acevedo S, Bengio R, Arrossagaray G, Watman N, Rossi N, et al. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Haematologica 2002;87:9-16.
25. Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome. Cancer 1988;62:958-64.
26. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995:91:612-7.
27. Pfeilstocker M, Reisner R, Nosslinger T, Gruner H, Nowotny H, Tuchler H, et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 1999;106:455-63.
28. Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000;108:346-56.
29. Block AW, Carroll AJ, Hagemeijer A, Michaux L, van Lom K, Olney HJ, et al. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:401-12.
30. Paydas S, Kocak R. Younger age observation in myelodysplastic syndrome. Leuk Res 1996;20:367.
31. Mukiibi JM, Paul B. Myelodysplastic syndromes (MDS) in central Africans. Trop Geogr Med 1994;46:17-9
32. Andersen MK, Johansson B, Larsen SO, Pedersen-Bjergaard J. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica 1998;83:483-8.
33. Boultwood J, Lewis S, Wainscoat JS. The 5q- syndrome. Blood 1994;84:3253-60.
34. de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000;110:620-30.
35. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20: 2429-40